期刊簡介 | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | EMBO Molecular Medicine LetPub Score 8.8
50 ratings
Rate
Reputation 9.4 Influence 8.1 Speed 9.7 | ||||||||||||||||
期刊簡稱 | EMBO MOL MED | ||||||||||||||||
ISSN | 1757-4676 | ||||||||||||||||
E-ISSN | 1757-4684 | ||||||||||||||||
h-index | 90 | ||||||||||||||||
CiteScore |
| ||||||||||||||||
自引率 (2023-2024) | 1.10%自引率趨勢 | ||||||||||||||||
掲載範囲 |
| ||||||||||||||||
官方網站 | http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1757-4684 | ||||||||||||||||
在線稿件提交 | http://embomolmed.msubmit.net/cgi-bin/main.plex | ||||||||||||||||
開放訪問 | Yes | ||||||||||||||||
出版商 | Wiley-Blackwell | ||||||||||||||||
主題領域 | 医学 | ||||||||||||||||
出版國/地區 | ENGLAND | ||||||||||||||||
發行頻率 | 月刊 | ||||||||||||||||
創刊年 | 2009 | ||||||||||||||||
每年文章數 | 112每年文章數趨勢 | ||||||||||||||||
黃金OA百分比 | 53.50% | ||||||||||||||||
OA Related Info | APC: Yes( EUR6490; GBP5590; USD6890; ) APC waiver:Check Notes Other charges: No Keywords: molecular medicine、cell biology、translational medicine Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review、Double anonymous peer review | ||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1757-4676%5BISSN%5D | ||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Sort of slow, 4-8 Week(s) | ||||||||||||||||
競爭力 * | 來自作者的數據: Difficult | ||||||||||||||||
參考鏈接 |
| ||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
首頁 上一頁 1 下一頁 末頁 (頁 | |
[EMBO Molecular Medicine] 的評論 | 撰寫評論 |
作者: 安娜66 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-02-03 11:20:40 評論於 Hello, I would like to ask if it is necessary to submit all the raw data when submitting an article to this magazine? Thank you!(0) 讚! | 安娜66 |
作者: 辉夜一莹 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-10-06 21:26:36 評論於 Review speed: 2.0 | Submission acceptance rate: 25.0 Experience sharing: EMBO Press, the third sibling of EMBO, focuses mainly on clinical drug development. The number of submissions is not high, but the quality is good. Rejections are also quick. EMBO's journals are actually very good and won't waste your time. The editors are friendly(0) 讚! | 辉夜一莹 |
作者: 随意 領域: 生物学 審稿時間: 1.0 month(s) 結果: 拒稿 撰寫評論 |
2022-06-08 19:29:09 評論於 Rejected within three days of submission, they said it didn't meet the criteria for their magazine.(0) 讚! | 随意 |
作者: 建利少爷 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-04-01 13:35:50 評論於 Do you need to upload the original data?(0) 讚! | 建利少爷 |
作者: 昕靓小姐姐 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-04-01 08:51:24 評論於 Can you translate the following paragraph into English and Japanese, respectively, with headers ":" and ":"(0) 讚! | 昕靓小姐姐 |
作者: 金蛇海东 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-02-21 08:18:57 評論於 What is antibody validation data?(0) 讚! | 金蛇海东 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 23:11:15 評論於 The triple lines include top line, column line, bottom line, and other auxiliary lines can be added. The components of the three-line table include: table number, table title, item column, table body, table note(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-30 18:03:04 評論於 High resolution images (supporting file formats tiff, bmp, psd, gif, pdf) etc(0) 讚! | 维尔娜菲茨杰拉德 |
作者: 修然小公主 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-28 16:29:07 評論於 What is a three-line table?(0) 讚! | 修然小公主 |
作者: Oswald Edie 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-12-27 23:01:24 評論於 What format do general journals require for graphs and charts?(0) 讚! | Oswald Edie |
作者: 长安余妍 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2021-06-08 21:38:32 評論於 Is it considered under editorial consideration once submitted?(0) 讚! | 长安余妍 |
作者: 法慧和同 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2020-12-31 17:27:04 評論於 The score of EMBO Journal is approximately over 9 points, and the scores of several journals are generally stable. EMBO Molecular Medicine is expected to increase to 10 points in 2020. There were few journals with a score of 10 in the past, so EMBO Journal is relatively influential. However, as there are more and more journals with a score of over 10 now, its reputation is not as strong as before(0) 讚! | 法慧和同 |
作者: 重阳文景 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-04-18 21:51:23 評論於 Money is not a problem, as long as it can be issued, the unit's reward is enough to cover the layout fee. Mao Dading 2018-02-26 15:37:00 Published: OPEN ACCESS article, the layout fee is expensive, 3000 euros, various antibodies and so on need to be verified data, it is very cumbersome, in turn can be understood as high data reliability. IF is getting higher every year(0) 讚! | 重阳文景 |
作者: dianannan 領域: 医学 審稿時間: 1.0 month(s) 結果: 拒稿 撰寫評論 |
2019-03-30 11:20:35 評論於 It was under editorial consideration immediately, and be rejected in 5 days. But the rejection letter is far-fetched. But I can transfer it to other EMBO journals. (0) 讚! | dianannan |
作者: 玉卿姑娘 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2019-03-29 17:09:14 評論於 Under editorial consideration now, rejected in 5 days. However, the rejection letter seemed forced. But you can consider submitting to another EMBO journal(0) 讚! | 玉卿姑娘 |
作者: 折梅丁巳 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2018-02-26 18:50:41 評論於 Review speed: 1.0 | Submission acceptance rate: 50.0 Sharing experience: The article of OPEN ACCESS has a high publication fee of 3000 euros, and various antibodies require validation data, which is quite cumbersome. On the other hand, it can be understood as high data credibility. The impact factor is increasing every year(0) 讚! | 折梅丁巳 |
作者: 康平酱大魔王 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-12-06 12:35:40 評論於 How much is the layout fee?(0) 讚! | 康平酱大魔王 |
作者: 折梅丁巳 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2017-02-08 21:02:03 評論於 Articles in OPEN ACCESS journals are expensive in terms of publication fees, and validation data is required for various antibodies, making the process quite cumbersome. However, the Impact Factor is indeed increasing(0) 讚! | 折梅丁巳 |
首頁 上一頁 1 下一頁 末頁 (頁 |
Contact us